APGE
NEUTRALM&AApogee Therapeutics, Inc.
This is the 2026-08-27 snapshot — the signals and analysis for APGE as of this single trading day.
View full APGE research hub →Analysis
Apogee Therapeutics (APGE) is trading as a pure merger arbitrage play following its definitive agreement to be acquired by AbbVie for $135.11 per share in cash. Shareholders approved the $10.9 billion deal on August 11, 2026, pinning the stock mere cents below the buyout price and explaining the extremely low 1.6% realized volatility. The technical signals—QUIET_STORM, STEADY_CLIMB, and PERFECT_STACK—perfectly reflect this institutional absorption and lack of directional risk as the September 3 closing date approaches. While the broader market is in a highly supportive RISK_ON regime, APGE's price action is entirely insulated and dictated by the definitive M&A timeline, offering absolute conviction in the deal's imminent completion.
Fired Signals
Key Takeaways
- APGE is pinned near $134.96, offering a minimal arbitrage spread against the $135.11 all-cash acquisition price from AbbVie.
- Shareholders officially approved the merger, and Nasdaq has scheduled the stock to be halted on September 2, 2026, ahead of the September 3 closing.
- The exceptionally low realized volatility (1.6%) and steady volume confirm institutional confidence and virtually zero execution risk.